DBV Technologies
Develops epicutaneous immunotherapy (EPIT) patch technology for food allergies.
DBV | PA
Overview
Corporate Details
- ISIN(s):
- FR0010417345 (+3 more)
- LEI:
- 969500PVBQFWQKVDMD80
- Country:
- France
- Address:
- 107 AVENUE DE LA REPUBLIQUE, 92320 CHATILLON
- Sector:
- Manufacturing
Description
DBV Technologies is a clinical-stage biopharmaceutical company developing treatments for food allergies and other immunological diseases. The company's core technology is Viaskin®, a proprietary investigational platform based on epicutaneous immunotherapy (EPIT). This non-invasive patch technology is designed to re-educate the immune system by delivering minimal amounts of antigens through intact skin. DBV's lead product candidate, Viaskin Peanut (DBV712), is in late-stage clinical development for the treatment of peanut allergies in pediatric patients. The development pipeline also includes Viaskin Milk (DBV135) for milk allergies, with the platform holding potential for applications beyond food allergies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-06-06 23:00 |
DBV Technologies invitée à participer à une prochaine Conférence Investisseur
|
French | 135.3 KB | ||
| 2023-05-10 23:30 |
DBV Technologies Announces New England Journal of Medicine Publication of Phase…
|
English | 221.9 KB | ||
| 2023-05-10 23:30 |
DBV Technologies annonce la publication par le New England Journal of Medicine …
|
French | 211.4 KB | ||
| 2023-05-09 22:30 |
DBV Technologies invitée à participer à une prochaine Conférence Investisseur
|
French | 122.8 KB | ||
| 2023-05-09 22:30 |
DBV Technologies to Participate in Upcoming Investor Conference
|
English | 122.2 KB | ||
| 2023-05-04 22:30 |
DBV Technologies publie ses résultats financiers du premier trimestre 2023
|
French | 189.6 KB | ||
| 2023-05-04 22:30 |
DBV Technologies Reports First Quarter 2023 Financial Results
|
English | 174.9 KB | ||
| 2023-04-19 23:42 |
DBV Technologies présente une voie réglementaire pour Viaskin Peanut chez les e…
|
French | 191.6 KB | ||
| 2023-04-19 23:09 |
DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 – 3 …
|
English | 173.4 KB | ||
| 2023-04-12 22:30 |
DBV Technologies annonce les résultats de son Assemblée générale ordinaire et e…
|
French | 130.8 KB | ||
| 2023-04-12 22:30 |
DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary Gener…
|
English | 126.4 KB | ||
| 2023-03-24 21:30 |
Ordinary and Extraordinary General Meeting of April 12, 2023
|
English | 141.0 KB | ||
| 2023-03-24 21:30 |
Assemblée Générale Mixte du 12 avril 2023
|
French | 134.0 KB | ||
| 2023-03-16 14:17 |
Franchissement de seuils
|
French | 265.1 KB | ||
| 2023-03-16 14:11 |
Franchissement de seuils
|
French | 351.5 KB |
Automate Your Workflow. Get a real-time feed of all DBV Technologies filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for DBV Technologies
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for DBV Technologies via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-06-09 | N/A | Other | Other | 2,483,161 | 7,449,483.00 EUR |
Peer Companies
